Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

The user is currently using oral finasteride for hair loss and considering adding Eucapil, dutasteride mesotherapy, and microneedling to their treatment regimen. They are seeking alternatives to minoxidil, such as Stemoxydine, due to concerns about minoxidil's side effects.

Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.

The conversation humorously discusses exaggerated hair growth results using 500mg finasteride and 1000mg minoxidil daily, with side effects including a bloody nose and lowered libido. It also jokes about microneedling, hair transplants, and elephants, suggesting the post is satirical.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

Hair loss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.

This post and conversation are about the effects of Minoxidil on renal electrolytes transport in the Loop of Henle. The replies show a lack of interest and a brief summary stating that rectal Minoxidil electrolytes are bad.

The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.

User asks about Redensyl as a substitute for Minoxidil due to side effects. Another user suggests trying Ordinary Hair Serum with dermarolling for improved hair quality.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The conversation is about whether stopping Redensyl, unlike Minoxidil, allows you to maintain hair growth benefits. The user is considering Redensyl as an alternative to Minoxidil due to concerns about hair loss upon cessation of Minoxidil.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Taking Minoxidil topically for hair loss and the results, which included jokes about castration, Daenerys Targaryenism, and a hair system. People in the conversation also shared positive affirmations and humorous comments.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

User wants to mix finasteride into stemoxydine instead of minoxidil. Seeks stemoxydine brand recommendations for mixing in the UK.

The user is using topical minoxidil twice daily for hair regrowth and is hesitant to use finasteride due to concerns about hormonal effects. The conversation includes mixed opinions on the effectiveness of the treatment and suggestions to use a DHT blocker for better results.

Hair loss discussion mentions Minoxidil, Finasteride, and RU58841. User seeks opinions on Redensyl for hair regrowth and safety.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

A Danish citizen warns against NordicHairGrowth.com, claiming it falsely advertises products for treating androgenic alopecia. The company's ingredients and claims are disputed, including a non-existent patented ingredient RP-24, and a non-verifiable clinical trial.

This conversation discussed the potential for a hair loss treatment alternative to minoxidil, with many users debating the economic and health implications of such an option. Some suggested that finasteride could be used as an alternative, while others argued that this would ultimately not benefit pharmaceutical companies due to their reliance on planned obsolescence.

NAD⁺ precursors and EGCG may increase hair density, but users report mixed results with no significant hair gains. Some users suggest combining these with finasteride or dutasteride for better results.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

The conversation discusses using higher doses of minoxidil and finasteride, considering dutasteride, and exploring other treatments like RU58841 for hair preservation. The user reports no side effects after six months and is interested in advanced treatment combinations.